Drug intelligence / Profile preview

CTB006

Development stage: Unknown
Lead developer: 北京同为时代生物技术
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

CTB006 is a recombinant anti-human Death Receptor 5 (DR5) monoclonal antibody developed by Beijing Tongwei Times Biotechnology. It is designed to target and activate DR5 (also known as TRAIL-R2), a member of the tumor necrosis factor receptor superfamily that, upon ligation, triggers the extrinsic apoptotic pathway in cancer cells. By mimicking the pro-apoptotic activity of the TRAIL ligand, CTB006 aims to selectively induce programmed cell death in tumor cells while minimizing impact on normal tissues. The drug has been investigated in Phase 1 clinical trials in China as a monotherapy for patients with advanced solid tumors who have exhausted standard treatment options.

Other names: recombinant anti-human DR5 monoclonal antibody

Targets

TNFRSF10B (DR5)

Beyond the preview

Go deeper on CTB006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTB006.

Explore the full profile